Zero Friction Telemedicine Biomarkers
24/7 neurological health monitoring
at the push of a button.
The 15th International Conference on Alzheimers & Parkinsons Disease
nQ Medical is proud to ba a Gold Sponsor the AD/PD Conference.
Leveraging Patient Touch
nQ™ leverages the millions of everyday interaction patients naturally make with the world around them. By collecting this data with our Zero Friction model, we provide insights to healthcare providers. Six clinical studies have demonstrated our ability to detect the pathological signs of neurological disease sooner than the tools we have today.
Digital Biomarker Discovery Platform
Biomarker Discovery Platform of data modeling that can be
adapted cross-disorder and readied for rapid scaling.
Patented Technology for Clinical Trials
Our AI technology supports clinical trials by improving accuracy and efficiency in recruitment, 24/7, passive monitoring of disease progression from home by measuring the impact of therapy on outcomes at a far more granular level than current gold standards.
What Specialists Think
In a recent survey† of 2,305 movement disorder specialists, 95% of respondents indicated that the ability to monitor patients remotely is extremely valuable, very valuable or valuable.
Of current methods for the detection and monitoring of Parkinson’s Disease that are most in need of improvement, they single out:
- The specificity and sensitivity of collected data for critical decision making (76%)
- The lack of access to real-world, at home, patient data (56%)
- The subjective nature of data collecting (55%)
Furthermore, specialists feel that the availability of remote monitoring and disease progression data, like nQ provides, could potentially positively impact patient care by:
- Helping more accurately titrate medication (72%)
- Providing useful data to support treatment decisions (71%)
- Encouraging patients to become more involved in therapy (63%)
- Improving patient adherence to medication (53%)
- Assisting patients and caregivers better understand and manage the disease (50%)
The specialists have spoken, and we are on the same page.
† Areas of improvement in tools currently available for early detection and disease monitoring of Parkinson’s. US Movement Disorder Specialist Survey. SERMO. February 19, 2019.
Our Clinical Partners
Peer Reviewed Clinical Publications
Scientific Reports, 2015
In this proof of concept study, nQ demonstrated that daily interaction with a computer keyboard can be employed as means to observe and potentially quantify psychomotor impairment. This initial work in sleep inertia demonstrates that clinically relevant motor function changes can be measured by timing key press/release events from a typing routine on a physical keyboard, irrespective of the language or the typed text.
IEEE Transactions on Biomedical Engineering, 2017
In this study nQ presented our first result from the analysis of data gathered using smartphones. We showed that we can accurately discriminate an early PD population with mild Parkinsonian signs from a healthy control group by comparing the typing patterns from their interaction with touchscreen keyboards.
Movement Disorders, 2019
Recent advances in technology are opening new opportunities to remotely evaluate motor features in people with Parkinson’s. This study showed that using nQ to monitor typing, a habitual behavior facilitated by the nigrostriatal dopaminergic pathway, could allow for objectively and non-obtrusively monitoring Parkinsonian features and response to medication in an at‐home setting.
Scientific Reports, 2016
In nQ’s first study focused on Parkinson’s Disease, we showed data indicating that the routine interaction with computer keyboards can be used to detect motor signs in the early stages of Parkinson’s. We presented a solution that relies on keystroke data from daily use of personal computers and converts it into a PD motor index.
Journal of Medical Internet Research, 2018
This publication is on the value of nQ as a remote monitoring tool for Parkinson’s. The paper compares nQ’s performance in-clinic and at-home and showed that it provides similar quality measurements as a traditional in-clinic evaluation.
NQ Medical’s Software has been designated Breakthrough Status but is is not yet cleared by FDA. Any depictions of the technology are intended to be conceptual and illustrative and are not intended to convey exact representations of anatomy, physiology, structure, positioning, or performance of the technology.